Netupitant D6
| Product Name | Netupitant D6 |
|---|---|
| Alternate Names | Netupitant Stable Isotopes, Stable Isotopes of Netupitant |
| CAT No. | CS-O-03642 |
| CAS No. | 2070015-31-3 |
| Category | Stable Isotopes |
| Stock | IN-Stock |
| Mol. Wt. | 584.63 g/mol |
| Mol. For. | C₃₀H₂₆D₆F₆N₄O |
| Hazardous | This is a Hazardous Compound |
| COA | View Sample COA |
| MSDS | View Sample MSDS |
| Parent API | Netupitant |
| Purity | 99.62 |
| Therapeutic | Anti-Cancer / Oncology |
| Smileys | CN(C1=CN=C(N2CCN(C)CC2)C=C1C(C=CC=C3)=C3C)C(C(C([2H])([2H])[2H])(C4=CC(C(F)(F)F)=CC(C(F)(F)F)=C4)C([2H])([2H])[2H])=O |
| Controlled | No |
| Shipping | Free for purchase above 1000$ |
| Delivery | In-Stock, products will be dispatched within 24 hours via FedEx for USA, Europe, and other countries. |
| Return | Returns/replacement accepted if you are not satisfied with the quality of the product, (please send us an email with the reason/issues which are facing, within 15 days, after receipt of the product). |
| Ordering | Place your order online or by email sales@clearsynth.com |
Netupitant D6 is a deuterated form of netupitant, a highly potent and selective neurokinin-1 receptor antagonist used in the prevention of chemotherapy-induced nausea and vomiting. It is a white to off-white powder with a molecular weight of 438.5 g/mol and a chemical formula of C23H21D6F3N4O.
Netupitant D6 works by blocking the binding of substance P to the neurokinin-1 receptors in the brain, which prevents the activation of the vomiting reflex pathway. It has a long duration of action, with a half-life of approximately 90 hours, and is administered orally in combination with palonosetron, a 5-HT3 receptor antagonist.
In clinical studies, netupitant D6 has demonstrated superior efficacy in preventing acute and delayed nausea and vomiting compared to standard therapies. It has also been shown to be well-tolerated, with minimal side effects such as constipation, headache, and fatigue.
As with any medication, netupitant D6 should only be used under the guidance of a healthcare professional. It is contraindicated in patients with severe hepatic impairment and may interact with other medications, including those metabolized by CYP3A4.
Overall, netupitant D6 represents a significant advancement in the management of chemotherapy-induced nausea and vomiting, providing patients with a safe and effective option for reducing the debilitating side effects of cancer treatment.
Get an Instant Quote
Related Compounds
N-desmethyl netupitant D6 | Netupitant D8 | Netupitant N-oxide D6 | Monohydroxy Netupitant D6 |